Intrexon Corp  

(Public, NYSE:XON)   Watch this stock  
Find more results for Darryl Webster
45.93
+0.25 (0.55%)
Jul 2 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 45.50 - 47.13
52 week 16.13 - 51.44
Open 46.11
Vol / Avg. 1.12M/1.09M
Mkt cap 4.99B
P/E     -
Div/yield     -/0.35
EPS -0.62
Shares 109.25M
Beta     -
Inst. own 87%
Aug 12, 2015
Q2 2015 Intrexon Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 3, 2015
Intrexon Corp at Jefferies Global Healthcare Conference
May 12, 2015
Intrexon Corp at Bank of America Merrill Lynch Health Care Conference
May 11, 2015
Q1 2015 Intrexon Corp Earnings Call
May 11, 2015
Q1 2015 Intrexon Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 82.01% -111.71%
Operating margin -257.39% -97.26%
EBITD margin - -82.78%
Return on average assets 15.95% -15.37%
Return on average equity 21.20% -21.78%
Employees 480 -
CDP Score - -

Address

1750 Kraft Dr Ste 1400
BLACKSBURG, VA 24060-6147
United States - Map
+1-301-5569809 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Company’s technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.

Officers and directors

Randal J. Kirk Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Rick L. Sterling CPA Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Krish S. Krishnan Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Gregory I. Frost Ph.D. Senior Vice President - Health Sector
Age: 43
Bio & Compensation  - Reuters
Thomas Richard Kasser Ph.D. Senior Vice President - Food Sector
Age: 60
Bio & Compensation  - Reuters
Suma M. Krishnan Senior Vice President - Product Development
Age: 49
Bio & Compensation  - Reuters
Nir Nimrodi Senior Vice President - Corporate Development and Environment Sector
Age: 45
Bio & Compensation  - Reuters
Jeffrey T. Perez Senior Vice President — Intellectual Property Affairs
Age: 43
Bio & Compensation  - Reuters
Robert F. Walsh III Senior Vice President - Energy Sector
Age: 56
Bio & Compensation  - Reuters
Darryl Webster Senior Vice President - Intellectual Property
Age: 54
Bio & Compensation  - Reuters